Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Monday announced the availability of the US Food and Drug Administration (USFDA) approved Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP.
According to the company, the Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP is available as 7.5 ml fill in a 10 ml bottle.
The company added that Dexamethasone 0.1% Otic Suspension, USP is the therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension. The Ciprodex brand had US sales of approximately USD453m MAT for the most recent 12 months ending in June 2020 according to IQVIA Health.
In addition, the company said its ciprodex is indicated for the treatment of infections caused by susceptible isolates of Acute Otitis Media in paediatric patients with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa, as well as Acute Otitis Externa in paediatric, adult and elderly patients due to Staphylococcu.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US